Arvate HR. Major clinical outcomes of the action of the co-agonist tirzepatide to liraglutide and semaglutide in the treatment of obesity and type 2 diabetes mellitus: a systematic review. IJN [Internet]. 2025 Jan. 8 [cited 2025 Jul. 2];18(1). Available from: https://ijn.zotarellifilhoscientificworks.com/index.php/ijn/article/view/400